Madrigal Pharmaceuticals Inc (MDGL)
333.39
+10.15
(+3.14%)
USD |
NASDAQ |
Jan 08, 16:00
333.58
+0.19
(+0.06%)
After-Hours: 20:00
Madrigal Pharmaceuticals SG&A Expense (Quarterly): 107.58M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
Corcept Therapeutics Inc | 73.74M |
89bio Inc | 10.50M |
ADMA Biologics Inc | 18.56M |
Matinas BioPharma Holdings Inc | 2.142M |
Viking Therapeutics Inc | 13.77M |